newsfilter
← Latest News
ClinicalTrials.gov·

DESAL-HEART: Hypertonic Saline Added to a Pre-declared Furosemide Dose in Acute Heart Failure - NCT07927127

DESAL-HEART is a multicenter, randomized, open-label, blinded-endpoint, mechanistic proof-of-concept trial conducted within the Heart Failure Efficacy and Research Trial (HEART) Platform. The study will evaluate whether adding a single infusion of 3% hypertonic saline solution (HSS) to a pre-declared intravenous furosemide dose improves decongestion in patients hospitalized with acute heart failure.

Company
University of Alberta
Keywords
Acute Heart Failure (AHF), Acute Decompensated Heart Failure, DESAL-HEART, Hypertonic Saline, 3% Sodium Chloride, Furosemide, Loop Diuretics, Acute Heart Failure, Decongestion, Diuretic Response, HEART Platform, NT-proBNP